Liu Jian, Liu Jing, Guo Su-Yang, Liu Hong-Li, Li Sheng-Ze
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China.
Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City 233004, Anhui Province, China.
Asian Pac J Trop Med. 2017 Feb;10(2):184-188. doi: 10.1016/j.apjtm.2017.01.020. Epub 2017 Jan 29.
To study the regulating effect of HSP70 inhibitor (PES) combined with cisplatin on cervical cancer proliferation in vitro and transplanted tumor growth.
Cervical cancer Hela cell lines were cultured and divided into control group, cisplatin group, PES group and cisplatin + PES group that were treated with serum-free DMEM, cisplatin with final concentration of 10 μmol/L, PES 20 μmol/L and cisplatin 10 μmol/L combined with PES with 20 μmol/L, respectively; animal models with cervical cancer xenografts were established and divided into control group, cisplatin group, PES group and cisplatin + PES group who received intra-tumor injection of normal saline, 10 μmol/L cisplatin, 20 μmol/L PES as well as 10 μmol/L cisplatin + 20 μmol/L PES, respectively. Cell proliferation activity, transplanted tumor volume and mitochondria apoptosis molecule expression were detected.
Cell viability value and Bcl-2 mRNA expression in cells of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in cells were significantly higher than those of control group; transplanted tumor volume and the Bcl-2 mRNA expression in transplanted tumor tissue of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in transplanted tumor tissue were significantly higher than those of control group.
HSP70 inhibitor combined with cisplatin can inhibit cervical cancer cell proliferation in vitro and transplanted tumor growth through mitochondrial apoptosis pathway.
研究热休克蛋白70（HSP70）抑制剂（PES）联合顺铂对宫颈癌体外增殖及移植瘤生长的调控作用。
培养宫颈癌Hela细胞系，分为对照组、顺铂组、PES组和顺铂+PES组，分别用无血清DMEM、终浓度为10μmol/L的顺铂、20μmol/L的PES以及10μmol/L顺铂与20μmol/L PES联合处理；建立宫颈癌异种移植动物模型，分为对照组、顺铂组、PES组和顺铂+PES组，分别瘤内注射生理盐水、10μmol/L顺铂、20μmol/L PES以及10μmol/L顺铂+20μmol/L PES。检测细胞增殖活性、移植瘤体积及线粒体凋亡分子表达。
顺铂组、PES组和顺铂+PES组细胞的细胞活力值及Bcl-2 mRNA表达均显著低于对照组，而细胞中Bax、Caspase-3和Caspase-9 mRNA表达均显著高于对照组；顺铂组、PES组和顺铂+PES组移植瘤体积及移植瘤组织中Bcl-2 mRNA表达均显著低于对照组, 而移植瘤组织中Bax、Caspase-3和Caspase-9 mRNA表达均显著高于对照组。
HSP70抑制剂联合顺铂可通过线粒体凋亡途径抑制宫颈癌体外细胞增殖及移植瘤生长。
